Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

PSMA
Biological Pathway Review

Advertisement

Advertisement

PSMA Expression in Cancer

Bladder Cancer

Compared with normal urothelium, bladder cancer tissue expresses very high levels of PSMA. PSMA is an emerging biomarker for diagnosis and therapy of transitional cell carcinoma.4

Breast Cancer

Up to 60% of patients with breast cancer expressed PSMA-positive endothelia with the FOLH1 gene corresponding with invasive breast cancer. PSMA expression correlated with tumor grade and NST subtype, especially for patients with HER2-positive status. PSMA levels approached almost five times that of other tumors in triple-negative carcinoma cases.5

Colorectal Cancer

Approximately 75% of all colorectal cancer cases express PSMA positivity. Furthermore, PSMA expression was strongly associated with vascular invasion and distant metastasis.6

Prostate Cancer

PSMA is expressed in all cases of primary prostate adenocarcinomas and benign prostatic tissue as well as 98% of cases involving lymph node metastatic patterns.7

Renal Cell Carcinoma

PSMA expression occurs in >75% of clear cell renal carcinoma and >20% of transitional cell carcinoma cases.8 Monoclonal antibody therapy targeting PSMA may prove to be beneficial in the diagnosis and therapy of renal cell carcinoma.9

PSMA Biological Pathways Reviews

PSMA

Prostate-specific membrane antigen (PSMA), a zinc-dependent, transmembrane metallopeptidase, is known by other names in the literature, including GCPII, NAALADase and FOLH1.1 These designations were assigned based on organ-specificity or functionality.1 PSMA expression is replete in all types of prostatic tissue and can also be found in the CNS with implications for diagnostics and targeted therapy.1,2
PSMA is responsible for facilitating integrin transduction and PAK activation in a negative feedback loop.3 By interfacing with various peptidases, PSMA can modulate angiogenesis, which plays an important role in tumor growth and metastasis.3 Furthermore, as opposed to prostate-specific antigen, PSMA is not secreted, thereby proving to be a valuable marker in monoclonal antibody therapy.2 

Videos

Dr Tagawa
Videos
Dr Tagawa Discusses Study Results of Actinium J591 for mCRPC
06/22/2021
Scott Tagawa, MD, MS, FACP, discusses the background and findings of a phase 1 study on the use of a PSMA-targeted radionuclide therapy for patients with mCRPC.
Scott Tagawa, MD, MS, FACP, discusses the background and findings of a phase 1 study on the use of a PSMA-targeted radionuclide therapy for patients with mCRPC.
Scott Tagawa, MD, MS, FACP,...
06/22/2021
Oncology
Videos
Dr Feng Discusses Molecular Determinants of Response to APA in nmCRPC
02/20/2021
Felix Feng, MD, talks about identifying molecular determinants of response to apalutamide in nonmetastatic CRPC in the SPARTAN trial.
Felix Feng, MD, talks about identifying molecular determinants of response to apalutamide in nonmetastatic CRPC in the SPARTAN trial.
Felix Feng, MD, talks about...
02/20/2021
Oncology
Videos
Dr Tward Discusses CCR Scores Accurately Guiding Treatment for Prostate Cancer
02/16/2021
Jonathan Tward, MD, discusses how the link between clinical cell-cycle risk score and post-RT metastasis can identify patients eligible to forgo combined ADT.
Jonathan Tward, MD, discusses how the link between clinical cell-cycle risk score and post-RT metastasis can identify patients eligible to forgo combined ADT.
Jonathan Tward, MD, discusses...
02/16/2021
Oncology
Videos
Best Management Practices for a Patient With Early-Stage Non-Small Cell Lung Cancer
11/05/2024
Aakash Desai, MD, University of Alabama at Birmingham, discusses the course of treatment he would take for a patient with early-stage non-small cell lung cancer.
Aakash Desai, MD, University of Alabama at Birmingham, discusses the course of treatment he would take for a patient with early-stage non-small cell lung cancer.
Aakash Desai, MD, University of...
11/05/2024
Oncology
John Leonard, MD
Videos
Highlights in Novel Therapies for Lymphomas From the LL&M Congress
11/05/2024
In part 5 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses novel therapies for lymphomas with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 5 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses novel therapies for lymphomas with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 5 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
Highlights in Hodgkin Lymphoma From the LL&M Congress
11/05/2024
In part 4 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in Hodgkin lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 4 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in Hodgkin lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 4 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
Highlights in Diffuse Large B-Cell Lymphoma From the LL&M Congress
11/05/2024
In part 3 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in diffuse large B-cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 3 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in diffuse large B-cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 3 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
Highlights in Mantle Cell Lymphoma From the LL&M Congress
11/05/2024
In part 2 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in mantle cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 2 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in mantle cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 2 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
Jonathan Riess, MD
Conference Coverage
IO102-IO103 Plus Pembrolizumab Demonstrates Potential for Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
10/31/2024
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Jonathan Riess, MD, discusses...
10/31/2024
Oncology
Elisabeth Livingstone, MD
Conference Coverage
Early Switch From Targeted to Immunotherapy for Patients With Advanced BRAF V600-Positive Melanoma
10/31/2024
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Elisabeth Livingstone, MD,...
10/31/2024
Oncology
Andrea Botticelli, MD
Conference Coverage
Using Comprehensive Genome Profiling to Guide Treatment for Patients With Metastatic Solid Tumors
10/31/2024
Andrea Botticelli, MD, PhD, discusses final results from the phase 2 ROME trial which demonstrated that using comprehensive genome profiling to guide treatment can improve response and survival among pretreated patients with metastatic solid...
Andrea Botticelli, MD, PhD, discusses final results from the phase 2 ROME trial which demonstrated that using comprehensive genome profiling to guide treatment can improve response and survival among pretreated patients with metastatic solid...
Andrea Botticelli, MD, PhD,...
10/31/2024
Oncology
Sung Gwe Ahn, MD, PhD
Conference Coverage
Addition of Ovarian Function Suppression to Antihormonal Therapy Demonstrates Promise in HR-Positive, HER2-Positive Early Breast Cancer
10/31/2024
Sung Gwe Ahn, MD, PhD, discusses exploratory analysis results from the HERA trial which demonstrated that the addition of ovarian function suppression to antihormonal therapy shows promise in patients with HR-positive, HER2-positive early...
Sung Gwe Ahn, MD, PhD, discusses exploratory analysis results from the HERA trial which demonstrated that the addition of ovarian function suppression to antihormonal therapy shows promise in patients with HR-positive, HER2-positive early...
Sung Gwe Ahn, MD, PhD, discusses...
10/31/2024
Oncology
Giuseppe Viale, MD
Conference Coverage
Assessing HER2-Low/-Ultralow Status Could Change Treatment Landscape for Patients With HR-Positive Metastatic Breast Cancer
10/29/2024
Giuseppe Viale, MD, discusses results from a comparison study which demonstrated that reassessing local and central immunostaining results can identify more patients with HER2-low or HER2-ultralow expression eligible for trastuzumab...
Giuseppe Viale, MD, discusses results from a comparison study which demonstrated that reassessing local and central immunostaining results can identify more patients with HER2-low or HER2-ultralow expression eligible for trastuzumab...
Giuseppe Viale, MD, discusses...
10/29/2024
Oncology

Podcasts

Dr Saad Highlights Results Following the ACIS Study
Podcasts
Dr Saad Highlights Results Following the ACIS Study
02/20/2021
Fred Saad, MD, discusses the findings of ACIS, a phase 3 clinical trial of apalutamide and abiraterone acetate plus prednisone vs abiraterone alone for chemotherapy-naive CRPC.
Fred Saad, MD, discusses the findings of ACIS, a phase 3 clinical trial of apalutamide and abiraterone acetate plus prednisone vs abiraterone alone for chemotherapy-naive CRPC.
Fred Saad, MD, discusses the...
02/20/2021
Oncology
Podcasts
Enzalutamide–ADT Combo significantly Improves PFS in Metastatic Hormone-Sensitive Prostate Cancer
02/26/2019
Andrew J. Armstrong, MD, discusses the findings of his team’s recent study on the use of enzalutamide plus ADT versus ADT alone in patients with metastatic hormone sensitive prostate cancer.
Andrew J. Armstrong, MD, discusses the findings of his team’s recent study on the use of enzalutamide plus ADT versus ADT alone in patients with metastatic hormone sensitive prostate cancer.
Andrew J. Armstrong, MD,...
02/26/2019
Oncology
Podcasts
Apalutamide Significantly Delays Metastasis in SPARTAN Trial of Nonmetastatic CRPC
02/14/2019
Julie N. Graff, MD, discusses the promising results of the SPARTAN clinical trial of apalutamide in patients with nonmetastatic CRPC.
Julie N. Graff, MD, discusses the promising results of the SPARTAN clinical trial of apalutamide in patients with nonmetastatic CRPC.
Julie N. Graff, MD, discusses...
02/14/2019
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
Sacituzumab Govitecan Plus Pembrolizumab in the TROPHY-U-01 Trial
03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares...
03/07/2024
Oncology
Sara Hurvitz, MD, David Geffen School of Medicine – UCLA, Los Angeles, CA
Podcasts
Neoadjuvant Chemotherapy Plus HER2-Targeted Therapy for Early Stage HER2-Positive Breast Cancer
02/16/2023
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she...
02/16/2023
Oncology
Michael Hall, MD, Fox Chase Cancer Center
Podcasts
Advances in Genetic Testing for Patients With Gastrointestinal Cancers
12/20/2022
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his...
12/20/2022
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
Enfortumab Vedotin for Metastatic Urothelial Cancer After Progression on Platinum-Based Chemotherapy
11/15/2022
Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.
Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.
Petros Grivas, MD, PhD, shares...
11/15/2022
Oncology
OLN favicon
Podcasts
BRCAness May Predict Response to Platinum-Based Chemotherapy in Intrahepatic Cholangiocarcinoma
07/29/2022
Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.
Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.
Margherita Rimini, MD, discusses...
07/29/2022
Oncology
Ruth He, MD, Lombardi Comprehensive Cancer Center
Podcasts
Durvalumab Plus Chemotherapy Improves Outcomes in Biliary Tract Cancer Across Primary Tumor Locations
07/22/2022
Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...
Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...
Ruth He, MD, discusses findings...
07/22/2022
Oncology
Arndt Vogel, MD, Hannover Medical School
Podcasts
Pemigatinib for Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
07/14/2022
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Arndt Vogel, MD, shares results...
07/14/2022
Oncology
Petros Grivas, MD, Fred Hutchinson Cancer Center
Podcasts
Sacituzumab Govitecan Plus Pembrolizumab Yields Encouraging Response Rates in Metastatic Urothelial Cancer
06/22/2022
Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Petros Grivas, MD, shares...
06/22/2022
Oncology
Robert Jones, MD
Podcasts
Maintenance Therapy With Cabozantinib Shows No Significant Benefit vs Placebo for Metastatic Urothelial Carcinoma
06/21/2022
Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.
Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.
Robert Jones, MD, shares results...
06/21/2022
Oncology
David O'Malley
Podcasts
Part 2: Overcoming PARP Inhibitor and Platinum Resistance in Patients With Ovarian Cancer
06/20/2022
In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.
In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.
In part 2 of this 2-part podcast...
06/20/2022
Oncology

Resources

News
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan and Companion Diagnostic Agent for Metastatic, Castration-Resistant Prostate Cancer
04/14/2022
The FDA approved lutetium Lu 177 vipivotide tetraxetan and a companion diagnostic agent for PSMA–positive, metastatic, castration-resistant prostate cancer previously treated with an androgen receptor inhibitor and taxane-based chemotherapy.
The FDA approved lutetium Lu 177 vipivotide tetraxetan and a companion diagnostic agent for PSMA–positive, metastatic, castration-resistant prostate cancer previously treated with an androgen receptor inhibitor and taxane-based chemotherapy.
The FDA approved lutetium Lu 177...
04/14/2022
Oncology
News
Safety, Efficacy of PSMA-Targeting Agent Being Assessed in mCRPC
07/26/2021
Investigators behind the phase 3 SPLASH trial are evaluating the safety and efficacy of 177Lu-PNT2002 for patients with mCRPC.
Investigators behind the phase 3 SPLASH trial are evaluating the safety and efficacy of 177Lu-PNT2002 for patients with mCRPC.
Investigators behind the phase 3...
07/26/2021
Oncology
News
FDA Authorizes Study of 2 Novel Treatments for Patients With PSMA+ mCRPC
07/26/2021
Researchers receive FDA authorization to evaluate 2 novel PSMA theranostic treatments, for patients with mCRPC.
Researchers receive FDA authorization to evaluate 2 novel PSMA theranostic treatments, for patients with mCRPC.
Researchers receive FDA...
07/26/2021
Oncology
News
PSMA-Targeting Therapy Shows Promise, Precision in Patients With mCRPC
07/26/2021
177Lu-PSMA-617 met both primary end points and substantially improved OS and PFS outcomes in patients with PSMA+ mCRPC, according to the phase 3 VISION study.
177Lu-PSMA-617 met both primary end points and substantially improved OS and PFS outcomes in patients with PSMA+ mCRPC, according to the phase 3 VISION study.
177Lu-PSMA-617 met both primary...
07/26/2021
Oncology
News
Phase I Study of PSMA Targeted 225Ac-J591 Reveals Tolerability in mCRPC
07/13/2021
225Ac-J591 receives first human study with research in PSMA targeting and dose expansion capabilities during an ongoing phase I trial.
225Ac-J591 receives first human study with research in PSMA targeting and dose expansion capabilities during an ongoing phase I trial.
225Ac-J591 receives first human...
07/13/2021
Oncology
News
Adding ADT to Radiotherapy Improves PFS in Patients With Prostate Cancer
02/02/2021
Adding ADT to radiotherapy salvage treatment reduces clinical progression and death in patients with prostate cancer.
Adding ADT to radiotherapy salvage treatment reduces clinical progression and death in patients with prostate cancer.
Adding ADT to radiotherapy...
02/02/2021
Oncology
News
Elevated GGT Prognosticates Shorter OS in Patients With Metastatic CRPC
01/12/2021
Findings from a retrospective study suggest elevated GGT as an adverse prognosticator in patients with metastatic CRPC receiving enzalutamide.
Findings from a retrospective study suggest elevated GGT as an adverse prognosticator in patients with metastatic CRPC receiving enzalutamide.
Findings from a retrospective...
01/12/2021
Oncology
News
Rucaparib Shows Antitumor Efficacy in mCRPC With Deleterious BRCA Alteration
09/02/2020
In the phase 2 TRITON2 study, rucaparib yielded antitumor activity in patients with mCRPC and deleterious BRCA alteration.
In the phase 2 TRITON2 study, rucaparib yielded antitumor activity in patients with mCRPC and deleterious BRCA alteration.
In the phase 2 TRITON2 study,...
09/02/2020
Oncology
News
Adding Enzalutamide to ADT Extends OS in Patients With Nonmetastatic CRPC
06/10/2020
Enzalutamide plus ADT led to a longer median OS in patients with nonmetastatic CRPC and a rapidly rising PSA level than placebo plus ADT in a phase 3 clinical trial.
Enzalutamide plus ADT led to a longer median OS in patients with nonmetastatic CRPC and a rapidly rising PSA level than placebo plus ADT in a phase 3 clinical trial.
Enzalutamide plus ADT led to a...
06/10/2020
Oncology
News
More Testing Before Surveillance May Benefit Older Patients With Prostate Cancer
04/20/2020
Patients aged >65 years with biopsy-confirmed prostate cancer may benefit from additional testing before being actively surveilled.
Patients aged >65 years with biopsy-confirmed prostate cancer may benefit from additional testing before being actively surveilled.
Patients aged >65 years with...
04/20/2020
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology
News
Extended Lymphadenectomy Fails to Improve Survival Outcomes for Patients With Muscle-Invasive Bladder Cancer
11/05/2024
Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.
Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.
Results from the phase 2 SWOG...
11/05/2024
Oncology
News
Tumor Molecular Features Contribute Substantially to Overall Survival Disparities Among Patients With Colorectal Cancer
11/05/2024
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center...
11/05/2024
Oncology
News
First-Line Durvalumab Plus Platinum-Doublet Chemotherapy Prolongs Survival for Patients With Extensive-Stage Small Cell Lung Cancer
11/04/2024
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a...
11/04/2024
Oncology
News
Gilteritinib Following AlloHCT Shows No Improvement in Health-Related Quality of Life Among Patients With FLT3-ITD AML
10/31/2024
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy...
10/31/2024
Oncology
News
Safety of Encorafenib Plus Binimetinib and Pembrolizumab for Advanced BRAF V600-Mutant Melanoma
10/31/2024
A safety lead-in for the STARBOARD trial found that both doses of encorafenib under evaluation, in combination with binimetinib and pembrolizumab, demonstrated safety that was comparable to the known profile for each agent.
A safety lead-in for the STARBOARD trial found that both doses of encorafenib under evaluation, in combination with binimetinib and pembrolizumab, demonstrated safety that was comparable to the known profile for each agent.
A safety lead-in for the...
10/31/2024
Oncology
News
Novel Next-Generation Sequencing Assay Proves Accurate in Detecting Mutations Among Patients Advanced HR-Positive, HER2-Negative Breast Cancer
10/31/2024
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS...
10/31/2024
Oncology
News
Fedratinib Demonstrates Promising Efficacy for Second-Line Treatment of Myelofibrosis
10/31/2024
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
According to a phase 3 trial,...
10/31/2024
Oncology
News
Datopotamab Deruxtecan Significantly Improves Progression-Free Survival for Patients With HR-Positive, HER2-Negative Breast Cancer
10/29/2024
Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.
Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.
Primary results from the...
10/29/2024
Oncology

Interactive Features

Test Your Knowledge
Quiz: Can Large Antibodies Target PSMA Expression During mCRPC Treatment?
07/29/2021
True or False: Since small molecule ligands can target PSMA expression, this indicates that large antibodies cannot during mCRPC treatment.
True or False: Since small molecule ligands can target PSMA expression, this indicates that large antibodies cannot during mCRPC treatment.
True or False: Since small...
07/29/2021
Oncology
Test Your Knowledge
Quiz: Which Approach Offers Improved Safety with J591 for mCRPC?
07/29/2021
Which treatment approach demonstrates greater safety outcomes when using a full-length antibody to target PSMA, particularly with actinium J591, for patients with mCRPC?
Which treatment approach demonstrates greater safety outcomes when using a full-length antibody to target PSMA, particularly with actinium J591, for patients with mCRPC?
Which treatment approach...
07/29/2021
Oncology
Test Your Knowledge
Quiz: Which Therapy Provides Targeted Radiation Delivery for PSMA-Expressive mCRPC?
07/29/2021
Which type of therapy for PSMA-expressive mCRPC supports targeted radiation delivery to tumors and prevents excessive damage to normal tissue?
Which type of therapy for PSMA-expressive mCRPC supports targeted radiation delivery to tumors and prevents excessive damage to normal tissue?
Which type of therapy for...
07/29/2021
Oncology
Quiz
Osimertinib For Progressive EGFR-Mutated T790M-Negative NSCLC
04/25/2023
How did patients with EGFR-mutated T790M-negative non-small cell lung cancer that had progressed after treatment with TKIs and chemotherapy respond to osimertinib?
How did patients with EGFR-mutated T790M-negative non-small cell lung cancer that had progressed after treatment with TKIs and chemotherapy respond to osimertinib?
How did patients with...
04/25/2023
Oncology
Test Your Knowledge
L858R Mutation by Stage in EGFR-Mutated Lung Cancer
04/13/2023
Is there a difference in L858R mutation rates in EGFR-mutated lung cancer when stratified by stage?
Is there a difference in L858R mutation rates in EGFR-mutated lung cancer when stratified by stage?
Is there a difference in L858R...
04/13/2023
Oncology
Quiz
Are PD-L1 Scores Predictive of TP53 Mutation Rates?
02/13/2023
A study investigated a potential link between PD-L1 scores and TP53 tumor mutation.
A study investigated a potential link between PD-L1 scores and TP53 tumor mutation.
A study investigated a potential...
02/13/2023
Oncology
Quiz
Quiz: Targeted Therapies for EGFR-Mutant Lung Cancer
12/02/2022
What study recently provided an additional 2 years of data to support adjuvant osimertinib as treatment of EGFR-mutant lung cancer?
What study recently provided an additional 2 years of data to support adjuvant osimertinib as treatment of EGFR-mutant lung cancer?
What study recently provided an...
12/02/2022
Oncology
Test Your Knowledge
Quiz: Combination Therapies as Treatment Options for EGFR-Mutated Lung Cancer
11/30/2022
Which combination therapies are currently being evaluated in clinical trials as treatment options for patients with EGFR-mutated lung cancer?
Which combination therapies are currently being evaluated in clinical trials as treatment options for patients with EGFR-mutated lung cancer?
Which combination therapies are...
11/30/2022
Oncology
Quiz
Quiz: Which somatic missense non-synonymous single nucleotide polymorphisms were recently determined to be putative novel rare genetic markers for NSCLC?
10/12/2022
After analyzing a selected pool of oncogenes, which somatic missense non-synonymous single nucleotide polymorphisms did a first-of-its-kind study find to be deleterious in patients with non-small cell lung cancer?
After analyzing a selected pool of oncogenes, which somatic missense non-synonymous single nucleotide polymorphisms did a first-of-its-kind study find to be deleterious in patients with non-small cell lung cancer?
After analyzing a selected pool...
10/12/2022
Oncology
Quiz
Quiz: Amivantamab Outcomes vs Other Real-World Therapies for EGFR-Mutated NSCLC
07/25/2022
In the single-arm CHRYSALIS study, among patients with EGFR exon 20 insertion-mutated advanced NSCLC who progressed after platinum-based chemotherapy, what outcome did not improve when treated with amivantamab vs real-world therapies?
In the single-arm CHRYSALIS study, among patients with EGFR exon 20 insertion-mutated advanced NSCLC who progressed after platinum-based chemotherapy, what outcome did not improve when treated with amivantamab vs real-world therapies?
In the single-arm CHRYSALIS...
07/25/2022
Oncology
Medical
Test Your Knowledge
Quiz: How Does Tisagenlecleucel Affect Activity in ALL?
03/07/2022
True or false: Tisagenlecleucel does not affect activity in young patients with R/R B-cell ALL and adult patients with R/R DLBCL.
True or false: Tisagenlecleucel does not affect activity in young patients with R/R B-cell ALL and adult patients with R/R DLBCL.
True or false: Tisagenlecleucel...
03/07/2022
Oncology
Test Your Knowledge
Quiz: Is This Selective FGFR Inhibitor Safe to Treat Hematologic Malignancies?
02/25/2022
True or false: The FIGHT-101 trial revealed pemigatinib is unsafe for patients with FGFR mutant hematologic malignancies.
True or false: The FIGHT-101 trial revealed pemigatinib is unsafe for patients with FGFR mutant hematologic malignancies.
True or false: The FIGHT-101...
02/25/2022
Oncology
Test Your Knowledge
Quiz: Does This Pan-FGFR TKI Show Long-Term Efficacy?
02/25/2022
True or false: Erdafitinib, a pan-FGFR TKI, showed long-term efficacy for advanced urothelial carcinoma.
True or false: Erdafitinib, a pan-FGFR TKI, showed long-term efficacy for advanced urothelial carcinoma.
True or false: Erdafitinib, a...
02/25/2022
Oncology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement